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Potential new targets for antimalarial chemotherapy include parasite proteases, which are required for several cellular
functions during the Plasmodium falciparum life cycle. Four new derivatives of N-alkyl and N-benzyl-1,10-phenanthroline
have been synthesized. Those are (1)-N-methyl-1,10-phenanthrolinium sulfate, (1)-N-ethyl-1,10-phenanthrolinium sulfate, (1)-
N-benzyl-1,10-phenanthrolinium chloride, and (1)-N-benzyl-1,10-phenanthrolinium iodide. Those compounds had potential
antiplasmodial activity with IC50 values from 260.42 to 465.38 nM. Cysteine proteinase inhibitor E64 was used to investigate the
m e c h a n i s mo fa c t i o no fN-alkyl and N-benzyl-1,10-phenanthroline derivatives. A modiﬁed ﬁxed-ratio isobologram method was
used to study the in vitro interactions between the new compounds with either E64 or chloroquine. The interaction between
N-alkyl and N-benzyl-1,10-phenanthroline derivatives and E64 was additive as well as their interactions with chloroquine were
also additive. Antimalarial mechanism of chloroquine is mainly on the inhibition of hemozoin formation. As the interaction of
chloroquine and E64 was additive, the results indicated that these new compounds had a mechanism of action by inhibiting
Plasmodium proteases.
1.Introduction
The erythrocytic life cycle of Plasmodium, which is responsi-
bleforallclinicalmanifestationsofmalaria,beginswhenfree
merozoites invade erythrocytes. The intraerythrocytic para-
sites develop from small ring-stage organisms to larger, more
metabolically active trophozoites and then to multinucleated
schizonts. The erythrocytic cycle is completed when mature
schizonts rupture erythrocytes, releasing numerous invasive
merozoites. Proteases appear to be required for cleavage of
red blood cell ankyrin to facilitate host cell rupture and
subsequent reinvasion of erythrocytes by merozoites, and for
the degradation of hemoglobin ingested by intraerythrocytic
trophozoites [1, 2].
Extensive evidence suggest that the degradation of
hemoglobin is necessary for the growth of erythrocytic
malaria parasite, apparently to provide free amino acids
for parasite protein synthesis [3, 4]. In P. falciparum,
hemoglobin degradation occurs predominantly in tropho-
zoites and early schizonts, the stages at which the parasites
are most metabolically active. Trophozoite ingest erythrocyte
cytoplasm and transport it to a large central food vacuole. In
thefoodvacuole,intacthemeisreleasedfromhemoglobinto
form the major component of malarial hemozoin pigment
[5]. The food vacuole appears to be the site of action of a
number of existing antimalarials and also oﬀers opportuni-
ties for therapies directed against new targets. Antimalarial
drugs such as chloroquine and primaquine appear to act by2 Malaria Research and Treatment
preventing hemozoin formation. Other drugs, such as vinyl
sulfones, act by preventing globin hydrolysis [6].
Hemoglobin degradation within the parasite is an
ordered process involving at least three proteinases. Aspartic
proteinaseplasmepsin-I,isresponsiblefortheinitialcleavage
of the hemoglobin tetramer at the hinge position, the
Phe33-Leu34 bond in the α-globin chain. A second aspartic
proteinase, plasmepsin-II, has also been identiﬁed and may
have a role in the cleavage of denatured hemoglobin.
Falcipain, a cysteine proteinase, is implicated in the cleavage
of peptides from the denatured hemoglobin. The amino
acids resulting from this process are presumably used by the
parasite. Inhibitors of both cysteine and aspartic proteases
have antimalarial eﬀects [7, 8].
Halofantrine was an eﬀective drug against chloroquine-
resistant P. falciparum. The disadvantages of this drug
were its variation in bioavailability and the side eﬀect of
ventricular arhythmia. To overcome those disadvantages,
Yapi et al. [9] synthesized diaza-analogs of phenanthrene
by substituting the two nitrogen atoms in the phenan-
threne skeleton, and the 1,10-phenanthroline skeleton is
the most active compound in vitro on both chloroquine-
resistant (FcB1) and chloroquine-sensitive (Nigerian) strain
with an IC50 of about 0.13μM. Mustofa et al. [10]s y n -
thesized four new derivatives of N-alkyl and N-benzyl-
1,10-phenanthroline: (1)-N-methyl-1,10-phenanthrolinium
sulfate, (1)-N-ethyl-1,10-phenanthrolinium sulfate, (1)-N-
benzyl-1,10-phenanthrolinium chloride, and (1)-N-benzyl-
1,10-phenanthrolinium iodide. The in vitro antiplasmodial
activity of those new compounds showed that four deriva-
tives are active against P. falciparum FCR3 and D10 strains
withanIC50 of0.13–0.79μMwhiletheinvivoantiplasmodial
activity against P. berghei in Swiss mice has an ED50 of 2.08–
50.93mg/kg [11, 12]. The activity of N-alkyl and N-benzyl-
1,10-phenanthroline derivatives on hemozoin formation
inhibitory activity is lower than that of chloroquine [13].
The mechanism of action of halofantrine has been identiﬁed
as at hemoglobin degradation, and the interaction between
halofantrineandproteinaseinhibitorRo40-4388andE64are
antagonistic [7]. Based on these results, further study was
done to investigate the mechanism of action of those new
compounds on the protease enzymes of P. falciparum FCR3
in vitro.
2.MaterialsandMethods
2.1. Molecules Tested. Four derivatives of N-alkyl and N-
benzyl-1-10-phenanthroline were evaluated for their mech-
anism in inhibiting P. falciparum proteases in vitro.T h ef o u r
derivatives of N-alkyl and N-benzyl-1-10-phenanthroline
have been synthesized by Mustofa et al. [14] and Hadanu
et al. [15]. Identiﬁcation of the compounds was carried out
by means of infrared (IR) spectroscopy, proton nuclear mag-
netic resonance (1H-NMR) spectroscopy, carbon nuclear
magnetic resonance (13C-NMR) spectroscopy and mass
spectroscopy (MS). Quantitative structure-activity relation-
ship(QSAR)ofthese1,0-phenanthrolinederivativeswasalso
investigated. On the basis of the QSAR studies, there was
a correlation between antiplasmodial activity and electronic
parameters as represented by a linear function of activity
versus atomic net charge of certain atoms on the 1,0-
phenanthroline skeleton especially N-1 atom. Each molecule
was diﬀerent at the substituent on nitrogen atom in position
1 of the 1,10-phenanthroline skeleton (Figure 1). Cysteine
proteinase, transepoxysuccinyl-L-leucylamido-(4-guanido)-
butane (E-64) was purchased from Sigma and chloroquine
diphosphate was obtained from Konimex-Indonesia. In
this study, the mechanism of action of those compounds
on the inhibition of P. falciparum protease in vitro was
evaluated.
2.2. Parasite Cultivation. P. falciparum FCR3 was continu-
ously cultured and maintained by standard methods [16]
with type O erythrocytes suspended in complete culture
medium(pH7.3),whichconsistedofﬁlteredsterilizedRPMI
1640 solution supplemented with 500mg of gentamycin, 2g
of sodium bicarbonate, 6.2g of HEPES per liter, and 10%
type-O human serum. Incubation was in a candle jar at 37◦C
under an atmosphere of 5% CO2. The level of parasitemia
in the culture was kept between 2–5% with 5% hematocrit.
Parasite synchrony was maintained by serial treatments with
5% sorbitol.
2.3. In Vitro Antiplasmodial Activity. Drug sensitivity assay
was carried out in 96-well microtitration plates. In vitro
antiplasmodial activity was determined as described by
Contreras et al. [17]a n dL e b b a d[ 18]. Drugs were dis-
solved in dimethyl sulfoxide and prediluted with serum-
free medium. Dose response assay was carried out to obtain
the 50% inhibitory concentration (IC50) of the individual
drugs. Microplate was preincubated with 100uL of serially
diluted test drugs. Ring stage-infected erythrocytes (100μL
per well with 3% hematocrit and 2% parasitemia) were
incubated in triplicate with twofold serial dilution of each
drug for 72 hours. Each experiment was performed in
duplicate separate experiment. Parasitemia was measured
microscopically on thin smear stained with 5% Giemsa. The
n u m b e ro fp a r a s i t i z e dr e dc e l l sw a sc o u n t e di na p p r o x i -
mately 1,000 red cells and divided by 10 to calculate the
percentage (%) of parasitized cells. Red cells infected with
any stages of Plasmodium were counted as infected red
cells.Growthinhibitionwasexpressedaspercentparasitemia
compared with untreated control. Drug IC50 value was
calculated from the log of the drug concentration-response
relationship.
2.4. In Vitro Drug Combination Assay. Analysis of the combi-
nation eﬀects of N-alkyl and N-benzyl-1,10-phenanthroline
derivatives with protease inhibitor E64, and interaction
with chloroquine were determined by a modiﬁed ﬁxed-
ratio isobologram method [7, 8, 19]. In vitro antiplasmodial
activity of each compound was determined before drug
combination assay. The fractional inhibitory concentration
(FIC; FIC = IC50 of drug in the combination/IC50 of drug
when tested alone) of each drug was calculated and plotted
as an isobologram. The isobologram analysis evaluates theMalaria Research and Treatment 3
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Figure 1: N-alkyl and N-benzyl-1,10-phenanthroline derivatives.
nature of interaction of two drugs, that is, drug A and drug B
required to produce a deﬁned single-agent eﬀect (e.g., IC50),
when used as single agents, are placed on the x and y axes
in a two-coordinate plot, corresponding to (CA,0 )a n d( 0 ,
CB), respectively. The line connecting these two points is
the line of additivity. The concentrations of the two drugs
used in combination to provide the same eﬀect, denoted as
(CA,C B), are placed in the same plot. Synergy, additivity,
and antagonism are indicated when (CA,C B)i sl o c a t e d
below (concave line), a straight line and above (convex line),
respectively. Combination Index (CI), similar to isobolo-
gramanalysis,providesqualitativeinformationonthenature
of drug interaction, and CI, a numerical value calculated as
described below, also provides quantitative measure of the
extent of drug interaction. Drug combinations of either N-
alkylandN-benzyl-1,10-phenanthrolinederivativesandE64
or chloroquine were expressed as the sum of the fractional
inhibitory concentration (Σ FIC) or combination index (CI),
according to method of Zhao et al. [20]
CI =
CA.x
ICx.A
+
CB.x
ICx.B
. (1)
CA.x and CB.x are the concentrations of drug A and drug B
used in combination to achieve x% drug eﬀect. ICx.A and
ICx.B are the concentrations for single agents to achieve the
same eﬀect.

F I Cv a l u e sw e r ed e ﬁ n e da ss y n e r g i s m( <0.5),
antagonism (>4), and additive (unity) [21].
Drug concentrations for these assay were 0–1,300nM for
N-alkyl and N-benzyl-1,10-phenanthroline derivatives; 0–
3,000nM and 0–38.75nM for E64 and chloroquine, respec-
tively. Each combination was serially diluted and processed
as for the sensitivity assay, therefore allowing IC50 to be
calculated. To validate the eﬀect, the activity of chloroquine
in combination with E64 was assayed as a positive control.
Layout of drug combination assay in 96-well plate is shown
in Figure 2.
3. Results and Discussion
3.1. In Vitro Sensitivity of the Parasites to Antimalarial
Drugs and Proteinase Inhibitor. The IC50 data for all N-
alkyl and N-benzyl-1,10-phenanthroline derivatives tested,
chloroquinediphosphateandE64againstP.falciparumFCR3
are shown in Table 1. The ability of chloroquine to inhibit
parasite growth was shown to be more potent than that
of N-alkyl and N-benzyl-1-10 phenanthroline derivatives.
Chloroquine diphosphate was used to identify the sensitivity
of P. falciparum FCR3. As the IC50 was 24.28 ± 3.15nM,
therefore P. falciparum FCR3 used in this study was sensitive
against chloroquine.4 Malaria Research and Treatment
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Figure 2:Layoutofacombinationexperimentina96-wellplatewiththeconcentrationratiosofdrugAanddrugBpreparedassixsolutions.
When plates were prepared as described in the text, clear wells serve as aquadest, dot black wells serve as a parasite control (no drug, 0%
growthinhibition),andwellslabeled1to6serveasdrugwellsforsixdrugcombinationsolution,intriplicate,withthewellsinrowFholding
the lowest drug concentration. Both 96-well plates were prepared similarly, with row F2 representing solutions 4 to 6 in the second 96-well
plate. Drug A was (1)-N-alkyl and (1)-N-benzyl-1,10-phenanthroline derivatives, drug B was either E64 or chloroquine.
Table 1: In vitro antiplasmodial activity of N-alkyl and N-benzyl-
1-10 phenanthroline derivatives, chloroquine diphosphate and E64
against P. falciparum FCR3.
Compound Mean IC50
(nM) ± SD
(1)-N-methyl-1,10-phenanthrolinium sulfate 260 ± 40
(1)-N-ethyl-1,10-phenanthrolinium sulfate 465 ± 57
(1)-N-benzyl-1,10-phenanthrolinium chloride 328 ± 44
(1)-N-benzyl-1,10-phenanthrolinium iodide 273 ± 27
Chloroquine diphosphate 24 ± 3
E64 836 ± 13
3.2. Interaction between N-Alkyl and N-Benzyl-1-10 Phenan-
throline Derivatives and E64. Isobolograms for N-alkyl
and N-benzyl-1-10 phenanthroline derivatives-proteinase
inhibitor E64 are shown in Figure 3. The combination
between N-alkyl and N-benzyl-1-10 phenanthroline deriva-
tives and E64 against the FCR3 isolate demonstrated additive
antimalarial eﬀect.
The isobologram describing the cooperative inhibition
of parasite growth by N-alkyl and N-benzyl-1-10 phenan-
throline derivatives and proteinase inhibitor E64 showed a
slightly concave line and on the line of additivity, indicating
an additive eﬀect. The combination index (CI) values ranged
from 0.89 ± 0.18 to 1.07 ± 0.18 (Table 2). Thus, the
interactions between (1)-N-methyl-1,10-phenanthrolinium
sulfate; (1)-N-ethyl-1,10-phenanthrolinium sulfate; (1)-N-
benzyl-1,10-phenanthrolinium chloride, and (1)-N-benzyl-
1,10-phenanthrolinium iodide with E64 were additive.
3.3. Interaction between N-Alkyl and N-Benzyl-1-10 Phenan-
throline Derivatives and Chloroquine. Isobolograms for N-
alkyl and N-benzyl-1-10 phenanthroline derivatives and
chloroquine are shown in Figure 4. The interaction of
those compounds against FCR3 isolate were additive with
CI values ranging from 0.89 ± 0.18 to 1.07 ± 0.18
(Table 2). Chloroquine and protease inhibitor E64 in this
study interacted additivily against P. falciparum with CI
value 1.17 ± 0.19. The isobologram describing the additive
inhibition of parasite growth by N-alkyl and N-benzyl-1-10
phenanthroline derivatives and chloroquine showed slightly
convex line.
E64 is an irreversible cysteine protease inhibitor that
inhibit Plasmodium growth at the trophozoite stage,
causing accumulation of undegraded hemoglobin in the
food vacuole. Additivity of N-alkyl and N-benzyl-1,10-
phenanthroline derivatives and cysteine protease inhibitor
E64 has been proposed for those new compounds. This
inhibition has an eﬀect on the source of amino acids needed
for Plasmodium growth.
The observations of an additive eﬀect between chloro-
quine and cysteine protease inhibitor E64 or N-alkyl and
N-benzyl-1,10-phenanthroline derivatives would lead to
both reduction of hemozoin and inhibition of cysteine
proteases, such as those involved in host cell invasion by
merozoites [2]. Mungthin et al. [7] observed an antagonism
between cysteine protease inhibitor E64 and chloroquine,
amodiaquine, quinine, meﬂoquine, and halofantrine. This
diﬀerent result could be caused by the diﬀerent criteria used
to interpret CI value. They used criteria of CI of less than,
equal to, and more than 1 to indicate synergy, additive, and
antagonism, respectively.
The IC50 of protease inhibitor E64 was 836 ± 13nM.
This result indicated that E64 inhibited the Plasmodium
protease enzymes. Similar study conducted by Mungthin
et al. [7], showed the IC50 of E64 against chloroquine-
resistant isolate P. falciparum K1 and chloroquine-sensitive
isolate P. falciparum HB3 of 8,932 ± 744nM and 9,65
± 1,677nM, respectively. The eﬀect of cysteine protease
inhibitor E64 against chloroquine-resistant P. falciparum W2
and chloroquine-sensitive P. falciparum D6 was also per-
formed by Semenov et al. [8] and the IC50 values are about
8,000nM.TheIC50 ofE64onourstudywasmuchlowerthan
the previous studies and this could be due to the diﬀerences
inP.falciparumisolatesusedforassay.Basedonthosestudies
it showed that the eﬀect of protease inhibitor E64 is not
inﬂuenced by the chloroquine sensitivity of P. falciparum.Malaria Research and Treatment 5
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Figure 3: Isobologram showing therelationship between the FICs ofE64 and N-alkylandN-benzyl-1-10 phenanthroline derivatives against
Plasmodium falciparum FCR3.
Based on this study we concluded that the interaction
between N-alkyl and N-benzyl-1,10-phenanthroline deriva-
tives and E64 was additive as well as their interaction with
chloroquine. This result is diﬀerent from the previous study
by Mungthin et al. [7] that showed an antagonistic inter-
action between halofantrine and proteinase inhibitor E64.
1,10-Phenanthroline derivatives have phenanthrene skeleton
with substitution of two nitrogen atoms and alkylation’s
or benzylation on N-1 atom. Diﬀerent structures between
phenanthroline and 1,10-phenanthroline derivatives seem to
contribute to the diﬀerent mechanisms of action of those
compounds.
Combination drug regimens for the treatment of malaria
oftenachieveatherapeuticeﬃcacygreaterthanthatachieved
with monotherapy. Other beneﬁts may include decreased
toxicity, delay, or prevention of drug resistance development,
and favorable eﬀects of synergistic drug interaction [22].
N-alkyl and N-benzyl-1,10-phenantroline derivatives and
protease inhibitor E64 appear to act cooperatively to inhibit
hemoglobin degradation and merozoites reinvasion. Based6 Malaria Research and Treatment
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Figure4:IsobologramshowingtherelationshipbetweentheFICsofchloroquineandN-alkylandN-benzyl-1-10phenanthrolinederivatives
against Plasmodium falciparum FCR3.Malaria Research and Treatment 7
Table 2: Combination index of N-alkyl and N-benzyl-1,10-phenanthroline derivatives with E64 or with chloroquine on P. falciparum FCR3
in vitro.
Compound combination Combination Index (CI) Interaction
(1)-N-methyl-1,10-phenanthrolinium sulfate -- E64 1.00 ± 0.26 Additive
(1)-N-ethyl-1,10-phenanthrolinium sulfate -- E64 0.89 ± 0.18 Additive
(1)-N-benzyl-1,10-phenanthrolinium chloride -- E64 1.07 ± 0.18 Additive
(1)-N-benzyl-1,10-phenanthrolinium iodide -- E64 0.99 ± 0.03 Additive
Chloroquine -- E64 1.17 ± 0.19 Additive
(1)-N-methyl-1,10-phenanthrolinium sulfate -- Chloroquine 1.28 ± 0.30 Additive
(1)-N-ethyl-1,10-phenanthrolinium sulfate -- Chloroquine 1.54 ± 0.96 Additive
(1)-N-benzyl-1,10-phenanthrolinium chloride -- Chloroquine 1.56 ± 0.58 Additive
(1)-N-benzyl-1,10-phenanthrolinium iodide -- Chloroquine 1.53 ± 0.44 Additive
o nt h i ss t u d yi tm a yb ea p p r o p r i a t et ou s ec o m b i n a t i o n s
of such inhibitors to treat malaria. This study has only
identiﬁed the mechanism of action of N-alkyl andN-benzyl-
1,10-phenanthroline derivatives on P. falciparum FCR3,
furtherstudiesshouldbeperformedwithotherchloroquine-
resistant and -sensitive isolates in order to obtain more
comprehensive information concerning the mechanism of
action of these phenanthroline compounds.
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